Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL

Author(s): Massimo Breccia, Giuliana Alimena.

Journal Name: Current Drug Targets

Volume 10 , Issue 6 , 2009

Become EABM
Become Reviewer

Abstract:

Imatinib mesylate is currently the standard therapy for chronic myeloid leukemia (CML) patients. Despite the remarkable results achieved with imatinib, the emergence of resistance to this drug has become a significant problem. Several strategies have been developed to overcome imatinib resistance, including dose escalation of the drug, combination treatments or novel targeted agents. Nilotinib is a second-generation tyrosine kinase inhibitor 30-50 fold more potent than imatinib with high affinity and selectivity on BCR/ABL, active against a wide range of mutant clones, except T315I mutation. Phase II trials of nilotinib showed high activity in imatinib-resistant or intolerant CML patients; front-line treatment of chronic phase Ph+ CML demonstrated rapid and stable cytogenetic responses and increasing molecular responses. We here review the development of nilotinib and the efficacy data in phase II and front-line trials.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 6
Year: 2009
Page: [530 - 536]
Pages: 7
DOI: 10.2174/138945009788488468
Price: $58

Article Metrics

PDF: 12